The Pain Management segment focuses on developing and commercializing therapies to address postoperative pain. The key product in this segment is ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and meloxicam. Research and development activities include clinical trials to expand the indications and improve the efficacy of ZYNRELEF. The technology used is the Biochronomer drug delivery system, which provides extended-release of the active ingredients. This segment aims to improve patient outcomes by reducing pain and opioid use after surgery. Market positioning is strong due to the innovative approach to pain management. Future opportunities include expanding the use of ZYNRELEF in various surgical procedures and geographic markets. Regulatory aspects involve obtaining approvals from health authorities like the FDA and Health Canada. Partnerships with companies like CrossLink Life Sciences are crucial for sales and marketing.

The Oncology Care segment is dedicated to developing and commercializing therapies to prevent chemotherapy-induced nausea and vomiting (CINV). The primary products in this segment are SUSTOL (granisetron) and CINVANTI (aprepitant). Research and development efforts focus on improving the efficacy and convenience of these therapies. The Biochronomer technology is used to provide extended-release of the active ingredients. This segment aims to improve the quality of life for cancer patients undergoing chemotherapy by reducing the debilitating effects of nausea and vomiting. Market positioning is based on providing effective and convenient antiemetic treatments. Future opportunities include expanding the product portfolio and exploring new applications of the Biochronomer technology in oncology. Regulatory aspects involve obtaining and maintaining approvals from regulatory agencies. The company is also focused on partnerships to enhance market access and distribution.